| Pharmaceutical active ingredients: |
| Nonoxynol 9 |
| Available forms, composition and doses of Syn-A-Gen: |
| Ovules; Vaginal; Nonoxynol 9 |
| Syn-A-Gen medical category: |
| Human:ContraceptivesSpermicidal agentsSurfactants |
| Indications and usages, anatomical therapeutic chemical and diseases classification codes: |
| G02BB - Intravaginal contraceptives |
| Pharmaceutical companies: manufacturers, researchers, developers, local distributors and suppliers: |
| DemocalVifor Pharma |
| Trade name |
Active ingredients |
Pharmaceutical company |
|
Synacthen Depot | Tetracosactide Acetate | Novartis; Alliance Pharmaceuticals; Nycomed |
| Synacthene | Tetracosactide | Novartis; Institute of Pharmaceutical Research and Technology; Sigma-Tau Pharmaceuticals |
| Synacthene Retard | Tetracosactide; Zinc Chloride | Novartis; Institute of Pharmaceutical Research and Technology; Sigma-Tau Pharmaceuticals |
| Synadrenol | Metoprolol | Casa Keyerson |
| Synadrin | Prenylamine | Unidentified Pharmaceutical Company |
| Synagis | Palivizumab | Abbott; Medimmune; The Glory Medicina; Zuellig Pharma |
| Synalar | Fluocinolone Acetonide | Medicis Pharmaceutical Corporation; AFT Pharmaceuticals; Agencia Lei Va Hong; Astellas Pharma; AstraZeneca; Bioglan; Biomed, Singapore; Derma UK; DKSH; Edward Keller; Grunenthal; Janssen; Jolly Jatel Laboratoire; Minerva Pharmaceutical; Pharmed Import & Export; Sanofi-Aventis; Syntex; United Italian Trading; V.J. Bartlett; Valeo Pharma; Ventiv Health Magyarorszag; Yamanouchi |
| Synalar + DBO | Broxyquinoline; Fluocinolone Acetonide | Medicis Pharmaceutical Corporation; Roche; Syntex |
| Synalar Bi-Ophtalmic | Fluocinolone Acetonide; Neomycin Sulfate; Polymyxin B Sulfate | Medicis Pharmaceutical Corporation; GlaxoSmithKline |
| Synalar Bi-Otic | Fluocinolone Acetonide; Neomycin Sulfate; Polymyxin B Sulfate | Medicis Pharmaceutical Corporation |